CD4-IgG(2)

a heterotetramer comprising two chains of a CD4-human IgG2 heavy chain fusion protein & two chains of CD4-human kappa light chain fusion protein; neutralizes HIV 1 isolates; structure given in first source

Also Known As:

CD4 IgG2; CD4-IgG2; PRO 542; PRO-542

Networked: 6 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Carbohydrates: 22023
- Glycoconjugates: 1353
  - Glycoproteins: 24834
    - Membrane Glycoproteins: 2252
      - Cell Adhesion Molecules: 4858
        CD4 Immunoadhesins: 11
        CD4-IgG(2): 6
Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
- Peptides: 82426
  - Peptide Fragments: 373
    - Immunoglobulin Fragments: 976
      - Immunoglobulin Fc Fragments: 295
        CD4 Immunoadhesins: 11
        CD4-IgG(2): 6
Biological Factors: 2472
- Antigens: 143924
  - Surface Antigens: 5813
    - Cell Adhesion Molecules: 4858
      - CD4 Immunoadhesins: 11
        CD4-IgG(2): 6

Experts

1.	Bayes, M: 1 article (07/2004)
2.	Prous, J R: 1 article (07/2004)
3.	Rabasseda, X: 1 article (07/2004)
4.	Frank, Ines: 1 article (04/2004)
5.	Griffin, George E: 1 article (04/2004)
6.	Hu, Qinxue: 1 article (04/2004)
7.	Moore, John P: 1 article (04/2004)
8.	Pope, Melissa: 1 article (04/2004)
9.	Santos, John J: 1 article (04/2004)
10.	Shattock, Robin J: 1 article (04/2004)

Related Diseases

1.	Infections 04/19/2004 - "In contrast, direct targeting of HIV-1 by neutralizing mAb b12 and CD4-IgG2 (PRO-542) blocked both localized infection and viral dissemination pathways. " 04/01/1998 - "The results demonstrate that CD4-IgG2 effectively neutralizes primary HIV-1 isolates in vivo and can prevent the initiation of infection by these viruses." 04/01/1998 - "The current report demonstrates that CD4-IgG2 protects against infection by primary isolates of HIV-1 in vivo, using the hu-PBL-SCID mouse model. " 12/01/2000 - "The use of recombinant CD4-IgG2 in pediatric human immunodeficiency virus type 1 (HIV-1) infection was evaluated by single and multidose intravenous infusions in 18 children in a phase 1/2 study. " 09/01/2002 - "The fusion inhibitor T20 and CXCR4 antagonist AMD3100 are synergistic in vitro at blocking infection of PBMC with clinical isolates [115] and T20 combined with the CD4 inhibitor PRO 542 have synergistic in vitro effects, with more than 10-fold greater inhibition of R5, X4, and R5X4 strains than either agent alone [116]. "
2.	Prostatic Neoplasms (Prostate Cancer) 07/01/2004 - ".TNF.11D, adefovir dipivoxil, AdPEDF.11, AES-14, albumex, alefacept, alemtuzumab, aliskiren fumarate, alvimopan hydrate, aAminolevulinic acid hydrochloride, aminolevulinic acid methyl ester, anakinra, anti-IL-12 MAb, aprepitant, atazanavir sulfate, atrasentan, avanafil; Banoxantrone, BG-12, bimatoprost, bortezomib, bosentan; Calcipotriol/betamethasone dipropionate, caspofungin acetate, CBT-1, ciclesonide, clofarabine, conivaptan hydrochloride, CpG-7909, C-Vax, Cypher; DA-8159, DAC:GLP-1, darbepoetin alfa, darifenacin, duloxetine hydrochloride; Eculizumab, efalizumab, efaproxiral sodium, EGF vaccine, eletriptan, epratuzumab, erlotinib hydrochloride, escitalopram oxalate, ETC-642, etoricoxib, everolimus, exenatide; Gefitinib, IV gamma-globulin; Human insulin, gamma-hydroxybutyrate sodium; IDN-6556, iguratimod, imatinib mesylate, indiplon, ixabepilone; Laquinimod, LB-80380, lidocaine/prilocaineliraglutide, lopinavir, lopinavir/ritonavir, lucinactant; MAb-14.18, melatonin, MLN-591-DM1; NC-531, neridronic acid, nesiritide, neutrophil-inhibitory factor, niacin/lovastatin; Oblimersen sodium, olcegepant, oral Insulin, ORV-105; Palonosetron hydrochloride, PAmAb, pegaptanib sodium, peginterferon alfa-2a, pegvisomant, perifosine, pexelizumab, phenoxodiol, phenserine tartrate, pimecrolimus, pramlintide acetate, pregabalin, PRO-542, prostate cancer vaccine, PT-141; Ramelteon, rasagiline mesilate, rDNA insulin, reslizumab, rh-Lactoferrin, ribamidine hydrochloride, rosuvastatin calcium; S-8184l, SC-1, sorafenib, St. John's Wort extract, SU-11248; Taxus, telbivudine, tenofovir disoproxil fumarate, teriparatide, testosterone gel, tezosentan disodium, tipifarnib, tolvaptan, trabectedin, travoprost, travoprost/timolol, treprostinil sodium; Vardenafil hydrochloride hydrate; Xcellerated T cells, XR-5944; Yttrium 90 (90Y) ibritumomab tiuxetan; Ziconotide."
3.	Body Weight (Weight, Body) 04/01/1998 - "Passive administration of 10 mg of CD4-IgG2 per kg of body weight protected all animals against subsequent challenge with 10 mouse infectious doses of the laboratory-adapted T-cell-tropic isolate HIV-1(LAI), while 50 mg of CD4-IgG2 per kg protected four of five mice against the primary isolates HIV-1(JR-CSF) and HIV-1(AD6). "

Related Drugs and Biologics

1.	Lopinavir
2.	Interleukin 1 Receptor Antagonist Protein (Anakinra)
3.	Glucagon-Like Peptide 1 (GLP 1)
4.	Brain Natriuretic Peptide (Natrecor)
5.	Ritonavir (Norvir)
6.	Teriparatide (Parathar)
7.	Yttrium
8.	Vaccines
9.	Timolol (Blocadren)
10.	Testosterone (Sustanon)

Related Therapies and Procedures

1.	Intravenous Infusions